Search results
Results from the WOW.Com Content Network
The Duquenois–Levine test is a simple chemical color reaction test initially developed in the 1930s by Pierre Duquénois. To administer the test, a user simply has to mix the chemicals with a particle of the suspected substance; if the chemicals turn purple, this indicates the possibility of marijuana.
Cannabis use disorder (CUD), also known as cannabis addiction or marijuana addiction, is a psychiatric disorder defined in the fifth revision of the Diagnostic and Statistical Manual of Mental Disorders and ICD-10 as the continued use of cannabis despite clinically significant impairment. [2] [3]
Teen marijuana use (non-medical) in 2024 also declined for all three grades, with the percentage of students using marijuana in the last 12 months at 26% in 12th grade, 16% in 10th grade and 7% in ...
A dried cannabis flower. The short-term effects of cannabis are caused by many chemical compounds in the cannabis plant, including 113 [clarification needed] different cannabinoids, such as tetrahydrocannabinol, and 120 terpenes, [1] which allow its drug to have various psychological and physiological effects on the human body.
Attitudes toward marijuana in the U.S. are changing and, with them, so is the legal landscape — and questions about how all of these changes may impact teens and young adults.While marijuana use ...
The new study found that delta-8 use by high school seniors was higher in the South and the Midwest and in states where recreational marijuana isn’t legal. Delta-8 was also more likely to be ...
In 1987, the DSM-IIIR category "psychoactive substance abuse", which includes former concepts of drug abuse is defined as "a maladaptive pattern of use indicated by...continued use despite knowledge of having a persistent or recurrent social, occupational, psychological or physical problem that is caused or exacerbated by the use (or by ...
Seventy-four percent were using Suboxone to ease withdrawal symptoms while sixty-four percent were using it because they couldn’t afford drug treatment. The researchers noted: “Common reasons given for not being currently enrolled in a buprenorphine/naloxone program included cost and unavailability of prescribing physicians.”